October 28, 2013

Ruipu's performance in first three quarters of 2013 lower than expected

In the first three quarters of 2013, Tianjin Ruipu Biological Technology Co., Ltd.'s (Ruipu) net income topped RMB96.63 million (US$15.87 million). Though the amount was an increase of 5.5% on-year, it was slightly lower than expected.

During the same period, the company realised an operating income of RMB536 million (US$88.04 million), rose by 14.4% on-year.

The company's porcine circovirus type 2 (PCV2) vaccine made a star performance during this period. The sales of the vaccine brought in RMB90 million (US$14.76 million) for the company, surged by 64% on-year.

Ruipu is a leading animal health company in China, which specialises in the diagnosis, prevention, treatment and curing of animal diseases.